Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06363461
Other study ID # 239-13851-202
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date April 13, 2024
Est. completion date October 31, 2024

Study information

Verified date April 2024
Source Technoderma Medicines Inc.
Contact Arthur P. Bertolino, MD, PhD, MBA
Phone +1 6169281145
Email arthur.bertolino@innovationderm.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Randomized, Vehicle-controlled, Parallel Group Study of TDM-180935 in Atopic Dermatitis Patients


Description:

Protocol 239-13851-202 is a Phase 2a study entitled "A Randomized, Vehicle-Controlled, Parallel Group Study of Topical TDM-180935 to Evaluate the Preliminary Efficacy, Safety, Tolerability, and Pharmacokinetics in Atopic Dermatitis Patients". Eligible subjects (24) in the randomized portion of the study will be randomized (2:2:1:1) to 1 of the 4 groups (low dose vs high dose vs placebo 1 vs placebo 2) and treated for 8 weeks. Eligible subjects (6) in the PK (pharmacokinetics) cohort will be treated with the high dose in an open label fashion.


Recruitment information / eligibility

Status Recruiting
Enrollment 24
Est. completion date October 31, 2024
Est. primary completion date September 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. A) Patient is a male = 18 years old at Visit 1/Screening. B) Patient is a post-menopausal or surgically sterile female = 18 years old at Visit 1/Screening. 2. Patient has provided written informed consent. 3. Male patients who are sexually active with a female partner and are not surgically sterile must use a highly effective method of birth control as described in the informed consent form. Note: Male patients must refrain from sperm donation for at least 90 days after application of their last dose of IP (investigational product). 4. Patient has active mild or moderate AD with a modified-Eczema Area and Severity Index (m-EASI) score of 5-16 and a history of AD duration = 2 years. 5. Patient has an AD body surface area (BSA) between 3 and 12% in the area to be treated (excluding head/neck, hands/feet, genitalia, and intertriginous areas) at Baseline. 6. Patient is willing and able to apply the IP(s) as directed, comply with study instructions (including avoiding direct sunlight exposure to the areas of IP application), and commit to all follow-up visits for the duration of the study. Note: The use of topical sunscreen is permitted provided the patient has used the sunscreen previously and it does not contain any prohibited medications/ingredients. 7. Patient, in the investigator's opinion, is in good general health and free of any disease state or physical condition that might impair evaluation or exposes the patient to an unacceptable risk by study participation. 8. Patient agrees to apply a bland moisturizer as directed for the duration of the study. 9. Patient has normal renal and hepatic function as determined by the Visit 1/Screening laboratory results in the opinion of the investigator. 10. [For PK Cohort Only] Patient is a non-smoker, defined as not having smoked or used any form of tobacco or non-tobacco products containing nicotine in more than 6 months before Visit 2/Baseline. 11. [For PK Cohort Only] Patient has a body mass index (BMI) of 19 to 32 kg/m2 inclusive and body weight not less than 50 kg at Visit 1/Screening. Exclusion Criteria: 1. Patient has any dermatological disorders of the skin within 20 cm of the areas to be treated with the possibility of interfering with the application of the IP or examination method, such as fungal or bacterial infections, psoriasis, folliculitis, notable scarring (linear scar > 2.5 cm, etc.), or skin atrophy at Visit 2/Baseline. 2. Patient has any skin pathology or condition that, in the investigator's opinion, could interfere with the evaluation of the IP or requires use of interfering topical, systemic, or surgical therapy at Visit 2/Baseline. 3. Patient has any visible inflammatory skin disease, injury, or condition of their skin that could compromise patient safety and/or interfere with the evaluation of local or systemic assessments performed during the study. 4. Patient has a known or suspected malignancy at Visit 2/Baseline excluding basal cell skin cancer unless it is associated with the area to be treated per Exclusion Criterion no. 1. 5. Patient has a positive blood screen for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C antibody. 6. Patient has any condition, which, in the investigator's opinion, would make it unsafe for the patient to participate in this study, including clinically significant abnormal laboratory, or 12-lead electrocardiogram (ECG) findings during the screening period or Visit 2/Baseline prior to dosing of the IP. 7. Patient has a hospital admission or major surgery within 30 days prior to Visit 2/ Baseline or planned for during the study. 8. Patient is currently enrolled in an investigational drug, biologic, or device study. 9. Patient has used an investigational drug, investigational biologic, or investigational device treatment within 30 days or 5 half-lives, whichever is longer, prior to Visit 2/Baseline. 10. Patient has a history of prescription drug abuse, or illicit drug use within 6 months prior to Visit 1/Screening. 11. Patient has a history of alcohol abuse according to medical history within 6 months prior to Visit 1/Screening. 12. Patient has a positive screen for alcohol or drugs of abuse at Visit 1/Screening or Visit 2/Baseline. Note: Patients with a positive drug screen believed by the investigator to be the result of medically appropriate prescription medication use can be enrolled with Medical Monitor approval. 13. Patient has used topical cosmetic (excluding bland moisturizers), herbal, over-the- counter (OTC) or prescription products within areas to be treated within 2 weeks prior to dosing at Visit 2/Baseline. 14. Patient has used systemic prescription treatment for AD or that in the opinion of the investigator may affect the patient's AD (examples include, but are not limited to PDE4 (Phosphodiesterase-4) inhibitors, corticosteroids, immunomodulators, antimetabolites, antibiotics, retinoids, etc.) within 4 weeks prior to Visit 2/Baseline. Note: systemic corticosteroids do not include intranasal, inhaled, or ophthalmic corticosteroids for the management of allergies, pulmonary disorders, or other conditions. 15. Patient has used systemic biologic therapy (i.e., dupilumab) for AD or that in the opinion of the investigator may affect the patient's AD within 5 half-lives of the biologic therapy prior to Visit 2/Baseline. 16. Patient has been diagnosed with COVID-19 (Coronavirus Disease of 2019) within 4 weeks of Visit 1/Screening. 17. Patient is unable to communicate or cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function. 18. Patient has previously been treated with the IP. 19. Patient has a history of sensitivity to any of the ingredients in the IP. 20. Patient has ongoing or recent history of any other uncontrolled and/or clinically significant systemic disease or condition which, in the investigator's opinion, should exclude participation in the study. 21. [For PK Cohort Only] Patient has a donation or blood collection of more than 1 unit (approximately 450 mL) of blood (or blood products) or acute loss of blood during the 90 days prior to Visit 2/Baseline. 22. [For PK Cohort Only] Patient has used systemic prescription medications, herbal (including St John's Wort, herbal teas and garlic extracts) supplements within 14 days prior to dosing at Visit 2/Baseline. 23. [For PK Cohort Only] Patient has used systemic OTC medications or vitamins within 7 days prior to dosing at Visit 2/Baseline. (Note: Use of acetaminophen at < 3g/day is permitted). 24. [For PK Cohort Only] Patient received a live or live attenuated vaccine within 4 weeks of dosing at Visit 2/Baseline.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
TDM-180935 topical ointment 1.0%
Eligible patients in the randomized portion of the study will be randomized (2:2:1:1) to 1 of the 4 groups. The assigned drug will be applied once daily for 8 weeks, with application to the active lesions excluding head/neck, hands/feet, genitalia, and intertriginous areas.
TDM-180935 topical ointment 2.0%
Eligible patients in the randomized portion of the study will be randomized (2:2:1:1) to 1 of the 4 groups. The assigned drug will be applied once daily for 8 weeks, with application to the active lesions excluding head/neck, hands/feet, genitalia, and intertriginous areas.
TDM-180935 topical vehicle ointment 1
Eligible patients in the randomized portion of the study will be randomized (2:2:1:1) to 1 of the 4 groups. The assigned placebo will be applied once daily for 8 weeks, with application to the active lesions excluding head/neck, hands/feet, genitalia, and intertriginous areas.
TDM-180935 topical vehicle ointment 2
Eligible patients in the randomized portion of the study will be randomized (2:2:1:1) to 1 of the 4 groups. The assigned placebo will be applied once daily for 8 weeks, with application to the active lesions excluding head/neck, hands/feet, genitalia, and intertriginous areas.

Locations

Country Name City State
United States Site 7 Anderson South Carolina
United States Site 3 Austin Texas
United States Site 1 College Station Texas
United States Site 8 Covington Louisiana
United States Site 4 New Brighton Minnesota
United States Site 2 Norfolk Virginia
United States Site 5 Rolling Meadows Illinois

Sponsors (2)

Lead Sponsor Collaborator
Technoderma Medicines Inc. Therapeutics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Incidence (severity and causality) of any local and systemic AEs (adverse events) Collection of adverse events 8 weeks
Other Number of patients with presence (and severity) of the following LSRs (local skin reactions): skin pigmentation (hyperpigmentation and hypopigmentation), edema, erosion,scaling, and burning/stinging Collection of LSRs at weeks 2, 4, 6, and 8 8 weeks
Other Changes from Baseline in vital signs (temperature) Collection of temperature at weeks 4 and 8 8 weeks
Other Changes from Baseline in vital signs (systolic and diastolic blood pressure) Collection of systolic and diastolic blood pressure at weeks 4 and 8 8 weeks
Other Changes from Baseline in vital signs (heart rate) Collection of heart rate at weeks 4 and 8 8 weeks
Other Changes from Baseline in vital signs (respiration rate) Collection of respiration rate at weeks 4 and 8 8 weeks
Other Changes from baseline in clinical laboratory tests (including Blood Chemistries, Hematology, and Urinalysis) Collection of safety lab results at weeks 4 and 8 8 weeks
Other Number of participants with abnormal ECG readings Collection of ECGs at day1, week 4 and week 8 8 weeks
Primary Change in m-EASI (modified Eczema Area and Severity Index) score Collection of EASI (Eczema Area and Severity Index) results at week 8. The total m-EASI score may range from zero (0) to a maximum of 64.8, and higher scores mean a worse outcome. 8 weeks
Secondary Proportion of patients with a = 2 point improvement in vIGA-AD score (validated Investigator's Global Assessment for Atopic Dermatitis score) Collection of vIGA-AD score (validated Investigator's Global Assessment for Atopic Dermatitis score) at week 8. The vIGA-AD is a static morphological 5-point ordinal scale from 0 (clear) to 4 (severe). 8 weeks
Secondary Change in m-EASI (modified Eczema Area and Severity Index) score Collection of EASI (Eczema Area and Severity Index) results at weeks 2, 4, and 6. The total m-EASI score may range from zero (0) to a maximum of 64.8, and higher scores mean a worse outcome. 6 weeks
Secondary Proportion of patients with a 50% improvement in m-EASI (modified Eczema Area and Severity Index) score Collection of EASI (Eczema Area and Severity Index) results at week 8. The total m-EASI score may range from zero (0) to a maximum of 64.8, and higher scores mean a worse outcome. 8 weeks
Secondary Proportion of patients with a 75% improvement in m-EASI (modified Eczema Area and Severity Index) score Collection of EASI (Eczema Area and Severity Index) results at week 8. The total m-EASI score may range from zero (0) to a maximum of 64.8, and higher scores mean a worse outcome. 8 weeks
Secondary Proportion of patients with a 90% improvement in m-EASI (modified Eczema Area and Severity Index) score Collection of EASI (Eczema Area and Severity Index) results at week 8. The total m-EASI score may range from zero (0) to a maximum of 64.8, and higher scores mean a worse outcome. 8 weeks
Secondary Change in BSA (body surface area) affected Collection of BSA affected at weeks 2, 4, 6, and 8 8 weeks
Secondary Proportion of patients with a 4-point improvement from Baseline in WI-NRS (Worst Itch-Numeric Rating Scale) score Collection of WI-NRS (Worst Itch-Numeric Rating Scale) score at week 8. The level of itching is described on an 11-point scale anchored at 0, representing "no itch" and 10, representing, "worst itch imaginable". 8 weeks
See also
  Status Clinical Trial Phase
Completed NCT05018806 - Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis Phase 2
Completed NCT04090229 - A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis Phase 1
Terminated NCT03847389 - Clobetasol Topical Oil for Children With Moderate to Severe Atopic Dermatitis Phase 1/Phase 2
Active, not recruiting NCT05388760 - Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1) Phase 2
Completed NCT05530707 - Evaluation of Acceptability, Skin Barrier Restoration and Balance of Atopic Skin Using Moisturizer N/A
Completed NCT02595073 - Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis Phase 3
Recruiting NCT05509023 - Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD) Phase 2
Recruiting NCT05048056 - Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis Phase 2
Completed NCT04598269 - Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis Phase 2
Recruiting NCT03936335 - An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
Withdrawn NCT03089476 - Evaluating Skin Barrier Dysfunction in Infants at High Risk of Atopy N/A
Recruiting NCT05029895 - A Study to Evaluate Adverse Events and Change in Disease State of Oral Upadacitinib in Adolescent Participants Ages 12 to <18 Years Old Diagnosed With Atopic Dermatitis (AD)
Terminated NCT03654755 - Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis Phase 2
Completed NCT04556461 - Effects of Tralokinumab Treatment of Atopic Dermatitis on Skin Barrier Function Phase 2
Recruiting NCT04818138 - BROadband vs Narrowband photoTherapy for Eczema Trial Nested in the CACTI Cohort N/A
Completed NCT03719742 - A Clinical Study to Evaluate the Safety and Efficacy of a Baby Cleanser and a Moisturizer N/A
Completed NCT05375955 - A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis. Phase 2
Completed NCT03441568 - In-home Use Test of the New Modified Diprobase Formulation to Assess the Safety and Tolerability in Infants and Children Under Physician's Control N/A
Recruiting NCT06366932 - Optimization of Atopic Dermatitis Treatment That Requires Second-line Systemic Therapy Through Predictive Models Phase 4
Completed NCT03304470 - A Study to Evaluate the Safety and Efficacy of ATx201 in Subjects With Moderate Atopic Dermatitis Phase 2